IL214611A - In vitro method and kit based on gamma antitrone levels to evaluate the efficacy of cancer patient treatment with an immunosuppressant - Google Patents

In vitro method and kit based on gamma antitrone levels to evaluate the efficacy of cancer patient treatment with an immunosuppressant

Info

Publication number
IL214611A
IL214611A IL214611A IL21461111A IL214611A IL 214611 A IL214611 A IL 214611A IL 214611 A IL214611 A IL 214611A IL 21461111 A IL21461111 A IL 21461111A IL 214611 A IL214611 A IL 214611A
Authority
IL
Israel
Prior art keywords
assessing
efficacy
treatment
immunogenic composition
cancer patient
Prior art date
Application number
IL214611A
Other languages
English (en)
Hebrew (he)
Other versions
IL214611A0 (en
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of IL214611A0 publication Critical patent/IL214611A0/en
Publication of IL214611A publication Critical patent/IL214611A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL214611A 2009-03-24 2011-08-11 In vitro method and kit based on gamma antitrone levels to evaluate the efficacy of cancer patient treatment with an immunosuppressant IL214611A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305256 2009-03-24
PCT/EP2010/053755 WO2010108908A1 (en) 2009-03-24 2010-03-23 Biomarker for monitoring patients

Publications (2)

Publication Number Publication Date
IL214611A0 IL214611A0 (en) 2011-09-27
IL214611A true IL214611A (en) 2015-07-30

Family

ID=42153802

Family Applications (1)

Application Number Title Priority Date Filing Date
IL214611A IL214611A (en) 2009-03-24 2011-08-11 In vitro method and kit based on gamma antitrone levels to evaluate the efficacy of cancer patient treatment with an immunosuppressant

Country Status (20)

Country Link
US (1) US20120028279A1 (https=)
EP (1) EP2411815B1 (https=)
JP (1) JP5774578B2 (https=)
KR (1) KR20110138354A (https=)
CN (1) CN102362184B (https=)
AU (1) AU2010227611B2 (https=)
BR (1) BRPI1009892A2 (https=)
CA (1) CA2756133A1 (https=)
CO (1) CO6450670A2 (https=)
DK (1) DK2411815T3 (https=)
ES (1) ES2555858T3 (https=)
HU (1) HUE026194T2 (https=)
IL (1) IL214611A (https=)
MX (1) MX2011010061A (https=)
NZ (1) NZ595290A (https=)
RU (1) RU2542435C2 (https=)
SG (2) SG2014014021A (https=)
TW (1) TWI470225B (https=)
WO (1) WO2010108908A1 (https=)
ZA (1) ZA201106890B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
EP3605090A1 (en) * 2012-05-23 2020-02-05 F. Hoffmann-La Roche AG Selection method for therapeutic agents
US10799567B2 (en) * 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
EP3466446B1 (en) * 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
ATE298098T1 (de) * 1997-02-06 2005-07-15 Univ Dublin Elektrochromes system
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
EP0958826A4 (en) * 1997-03-07 2001-04-11 Akira Hayashi IMMUNOTHERAPEUTIC AGAINST CANCER CONTAINING NUCLEOID INGREDIENTS OF BACTERIA AS AN ACTIVE INGREDIENT
JPH10306029A (ja) * 1997-03-07 1998-11-17 Akira Hayashi 細菌の菌体成分を有効成分とする癌免疫療法剤
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9819726D0 (en) 1998-09-11 1998-11-04 Advanced Environmental Enginee Vapour recovery system
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
CA2362367C (en) 1999-02-04 2004-08-03 Geron Corporation Telomerase reverse transcriptase transcriptional regulatory sequences
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
ES2424131T3 (es) * 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
EP1509244B1 (en) * 2002-06-06 2011-07-27 Immunicum AB New method and composition for producing a cellular allogeneic vaccine
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
CN1889963A (zh) * 2003-10-10 2007-01-03 宝德杰克特疫苗有限公司 方法
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
AU2005205441A1 (en) * 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
WO2005118884A1 (en) * 2004-05-28 2005-12-15 The United States Of America As Represented By The Secretary Of The Navy A method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines
CN101035901A (zh) * 2004-07-22 2007-09-12 细胞基因系统有限公司 腺病毒载体中转基因的插入
ES2389562T3 (es) * 2004-10-25 2012-10-29 Statens Seruminstitut Antígenos de Chlamydia trachomatis para uso en vacuna y diagnóstico
EP1874342B1 (en) * 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
PL1896051T3 (pl) * 2005-06-28 2015-04-30 Oncothyreon Inc Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1)
JP2009526991A (ja) * 2006-02-17 2009-07-23 パオロ・ラ・コッラ 増殖性疾患及び／又はコンホメーション病の診断方法
JP5382529B2 (ja) * 2007-09-10 2014-01-08 独立行政法人理化学研究所 ヒト樹状細胞の評価方法およびヒト細胞免疫療法剤

Also Published As

Publication number Publication date
ES2555858T3 (es) 2016-01-11
MX2011010061A (es) 2011-11-18
CA2756133A1 (en) 2010-09-30
KR20110138354A (ko) 2011-12-27
HUE026194T2 (en) 2016-05-30
BRPI1009892A2 (pt) 2016-03-15
TW201038943A (en) 2010-11-01
AU2010227611A1 (en) 2011-08-25
SG174507A1 (en) 2011-10-28
EP2411815A1 (en) 2012-02-01
JP5774578B2 (ja) 2015-09-09
JP2012521549A (ja) 2012-09-13
TWI470225B (zh) 2015-01-21
CO6450670A2 (es) 2012-05-31
EP2411815B1 (en) 2015-11-11
DK2411815T3 (en) 2015-11-30
NZ595290A (en) 2012-09-28
WO2010108908A1 (en) 2010-09-30
SG2014014021A (en) 2014-07-30
CN102362184A (zh) 2012-02-22
ZA201106890B (en) 2012-06-27
AU2010227611B2 (en) 2014-05-29
RU2542435C2 (ru) 2015-02-20
HK1161644A1 (en) 2012-07-27
US20120028279A1 (en) 2012-02-02
RU2011142612A (ru) 2013-04-27
CN102362184B (zh) 2015-04-08
IL214611A0 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
GB0700560D0 (en) Device and method for the treatment of diseased tissue such as tumours
GB2509641B (en) Patient interface and aspects thereof
GB2494493B (en) Patient interface and aspects thereof
IL213410A0 (en) Methods and compositions for diagnostic use in cancer patients
EP2180873A4 (en) THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
EP2262450A4 (en) IMPLANTS AND METHODS OF USE
IL199797A0 (en) Methods and devices for heart tissue repair
GB0922085D0 (en) Cancer diagnosis and treatment
GB0910811D0 (en) Cochlear implant apparatus and methods
PT2614832T (pt) Diagnóstico de pré-eclâmpsia
IL214255A0 (en) Methods and compositions for diagnosis and treatment of cancer
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
IL236516A0 (en) Methods and preparations for the diagnosis and treatment of cancer
ZA201107583B (en) Dental implant assembly and component
IL205246A0 (en) Methods and compositions for diagnostic use in cancer patients
GB201108964D0 (en) Medicament and method of diagnosis
IL217748A0 (en) Methods and compositions for diagnostics use in cancer patients
ZA201103535B (en) An implantable medical device
IL214611A (en) In vitro method and kit based on gamma antitrone levels to evaluate the efficacy of cancer patient treatment with an immunosuppressant
GB0821512D0 (en) Medical gas administration device and kit
HU1000219D0 (en) Dental implant, dental abutment and dental kit
GB0608647D0 (en) Methods of diagnosis and treatment
GB0901837D0 (en) Cancer diagnosis and treatment
ZA201000609B (en) Homogeneous vaccine composition for the tumor treatment and its obtaining method

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees